1. Ермоленко В.М. Острая почечная недостаточность. Руководство для врачей. Нефрология. Под ред. И.Е.Тареевой. М.: Медицина, 2000; 580–95.
2. Bartels H. Acute renal failure. Langenbecks Arch Chir. Suppl. Kongressbd. 1997; 114: 185–7.
3. Lameire NH, Flombaum CD, Moreau D, Ronco C. Acute renal failure in cancer patients. Ann Med 2005; 37 (1): 13–25.
4. Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol 2000; 27 (3): 322–34.
5. Jeha S. Tumor lysis syndrome. Semin Hematol 2001; 38 (4 Suppl. 10): 4–8.
6. Flombaum CD. Acute renal failure and dialysis in cancer patients. Crit Care Clin 1988; 4 (1): 61–79.
7. Ozono S, Okajima E, Takashima K, Yoshida K, Hirao Y. Urological emergency for cancer patients. Gan To Kagaku Ryoho 1997; 24 (3): 292–6.
8. Гельфанд Б.Р., Филимонов М.И., Бурневич С.З. Абдоминальный сепсис. Рус. мед. журн. 1998; 6: 697–706.
9. Tetta C, Bellomo R, Ronco C. Artificial organ treatment for multiple organ failure, acute renal failure, and sepsis: recent new trends. Artif Organs 2003; 27 (3): 202–13.
10. Hoste EA, Kellum JA. Acute renal failure in the critically ill: impact on morbidity and mortality. Sepsis, Kidney and Multiple Organ Disfunction. Contrib Nephrol. Eds. C.Ronco, R.Bellomo, A.Brendolan. Basel, Karger, 2004; 144: 1–11.
11. Debets JM, Kampmeijer R, van der Linden MP et al. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989; 17 (6): 489–94.
12. Barriere SL, Lowry SF. An overview of mortality risk prediction in sepsis. Crit Care Med 1995; 23 (2): 376–93.
13. Hergert-Rosental S, Uppenncamp M, Beelen D et al. Renal complications of high-dose chemotherapy and peripheral blood stem cell transplantation. Nephron 2000; 84 (2): 136–41.
14. Hirasava K, Sugai T, Oda S. Acute renal failure following surgical insult. Nippon Geka Gakkai Zasshi. 1996; 97 (9): 765–70.
15. Bellomo R, Angus DC, Star RA. The Acute Dialysis Quality Initiative. II. Patient selection for CRRT. Adv Ren Replace Ther 2002; 9: 255–9.
16. Van Bommel EF. Should continuous renal replacement therapy be used for "non-renal" indications in critically ill patients with shock? Resuscitation 1997; 33 (3): 257–70.
17. Kielstein JT, Kretschmer U, Ernst T et al. Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study. Am J Kidney Dis 2004; 43 (2): 342–9.
18. Beckley S, Wajsman LZ, Pontes JE et al. Intermittent hemodialysis therapy in the cancer patient. J Surg Oncol 1982; 21 (4): 261–3.
19. Orlando MP, Dillon ME, O’Dell MW. Heparin-induced hyperkalemia confirmed by drug rechallenge. Am J Phys Med Rehabil 2000; 79: 93–6(B).
20. Schetz M. Anticoagulation in Continuous Renal Replacement Therapy. Blood Purification in Intensive Care. Contrib Nephrol. Eds. C.Ronco, R.Bellomo, G.La Greca. Basel, Karger, 2001; 132: 283–303.
21. Van Wijk V, Badenhorst PN, Luus HG, Kotze HE. A comparison between the use of recombinant hirudin and heparin during hemodialysis. Kidney Int 1995; 48: 1338–43 (B).
22. Martin PY, Chevrolet JC, Suter P, Favre H. Anticoagulation in patients treated by continuous venovenous hemofiltration: A retrospective study. Am J Kidney Dis 1994; 24: 806–12.
23. Pineo JF, Brain MC, Gallus AS. Tumors, mucin productions hypercoagulability. Ann NY acad Sci 1974; 230: 262–72.
24. Птушкин В.В. Фрагмин в онкологии. Совр. онкол. 2004; 6 (4): 1–7.
25. Бредер В.В., Горбунова В.А. Фрагмин в лечении и профилактике тромбоэмболических осложнений при онкологических заболеваниях: от теории к практике. Фарматека. 2003; 4: 1–4.
26. Weitz IC, Israel VK, Waisman JR et al. Chemotherapy-induced activation of hemostasis: effect of low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Thromb-Haemost 2002; 88: 213–20.
27. Kakkar AJ, Kadziola Z, Williamson RCN et al. Low molecular weight heparin therapy and survival in advanced cancer. Blood 2002; 100: 148a.
28. Lee AY, Julian JA, Levine MN, et al. Impact of dalteparin low molecular weight heparin (LMWH) on survival: results of a randomized trial in cancer patients with venous thromboembolism (VTE). Proc Am Soc Clin Oncol 22 2003; 846 (abstr): 211.
29. Sideras K, Schaefer PL, Okuno SH et al. Low-molecular weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 2006; 81 (6): 758–67.
30. Bick RL. Cancer-associated thrombosis: focus on extended therapy with dalteparin. J Support Oncol 2006; 4 (3): 115–20.
31. Dranitsaris G, Vincent M, Crowther M. Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis. Pharmacoeconomics 2006; 24 (6): 593–607.

Е.Г.Громова1, А.В.Маджуга2, О.В.Сомонова2, Л.С.Кузнецова1, А.Л.Елизарова2

1 Отделение реанимации и интенсивной терапии № 2 ГУ РОНЦ им. Н.Н.Блохина РАМН;
2 Клиническая лаборатория ГУ РОНЦ им. Н.Н.Блохина РАМН